FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19

Jessica HagmaierLTC News

Mary Madison, RN, RAC-CT, CDP
Clinical Consultant – Briggs Healthcare

On February 9, 2021 the FDA announced that an emergency use authorization (EUA) has been issued for “bamlanivimab and etesevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) who test positive for SARS-CoV-2 and who are at high risk for progressing to severe COVID-19. The authorized use includes treatment for those who are 65 years of age or older or who have certain chronic medical conditions. Read Full Story >>